TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Need for additional dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Course of factor II and factor X
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: neurocognitive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relative pain reduction of 50% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute pain reduction of at least 3 cm on the VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average ratings of pleasantness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of delivery of nicotine from the products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitudes towards breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in central systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: subsequent monthly earnings
Endpoint domain: Life impact
Endpoint subdomain: Economic functioning
Primary endpoint: steady-state area under the plasma concentration-time curve of telithromycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety measurements
Endpoint domain: Adverse events/effects
Primary endpoint: Spontaneous labour within 24 hours of prelabour rupture of membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Vaginal delivery within 24 hours of prelabour rupture of membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Perception of method of induction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CT-based fusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Chlamydia test not performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity impairment during pollen exposure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: improvements in disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean percentage aggregation with collagen on day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total income from public sources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: nights spent in 'own place' out of the previous 60 nights
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: days drinking out of the previous 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk for stroke or myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of developing colorectal adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: gain in proximal attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Plasma concentrations of IGF‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal delivery rate within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Neonatal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in liver volume (LV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conners' Adult ADHD Rating Scale Total ADHD Symptoms score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response (25% decrease on Conners' Adult ADHD Rating Scale Total ADHD Symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression‐ADHD‐Severity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythema post-treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Pain associated with laser treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Mean percentage improvement in facial telangiectasias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Extent and severity of reversible perfusion defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular perfusion pressure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate variability (rMSSD, HF, LF/HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal circumference change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karnofsky scoring
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: adverse reaction (myelosuppression)
Endpoint domain: Adverse events/effects
Primary endpoint: Partial remission rate
Endpoint domain: Mortality/survival
Primary endpoint: CD4+ lymphocyte count decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma cysteine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TNF-alpha level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Grade I and II toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: work engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: need for recovery
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: First desire to defecate threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Supraliminar pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prolonging the pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of newborn death
Endpoint domain: Mortality/survival
Primary endpoint: elevated levels of arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-perceived esthetic outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in functional parameters (HAQ and FFbH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain strength (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in functional limitations (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure death
Endpoint domain: Mortality/survival
Primary endpoint: Cancer death
Endpoint domain: Mortality/survival
Primary endpoint: short-term knowledge retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Failure-free rate at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient improvement over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop-out rates from CPN intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Preference for TRIO products over condoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to tablets and rings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Product-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: glucose rate of appearance in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hepatic insulin resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VLDL-apoB-100 concentration and secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: bacterial load on the hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: bacterial load on the fingertips
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: technical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric transit times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: relapse prevention of alcoholism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: daytime wrist activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety/depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of portal-vein thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Recruitment yield
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: S‐LVRR (≥15% reduction in left ventricular end‐systolic volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of heart failure (HF) or death
Endpoint domain: Mortality/survival
Primary endpoint: C(max)/C(min) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood transfusion requirements
Endpoint domain: Adverse events/effects
Primary endpoint: AIDS event or death
Endpoint domain: Mortality/survival
Primary endpoint: Angle of Progression (AOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head Perineal Distance (HPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of comprehensive MGDP transfer of care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence of a diagnostic cell block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State transitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FHR variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tolerability of carbamazepine
Endpoint domain: Adverse events/effects
Primary endpoint: Arteriovenous fistula functional maturation within 180 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing rate of large perforations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing time of large perforations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall bowel cleansing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAD incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attainment of supported sitting
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Attainment of supported walking
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neuropsychological test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amount of oral pathogens in enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Demineralization around restorations in enamel and dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion depths in enamel and dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCO (Posterior Capsule Opacification) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nodules
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction with advance care planning sessions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: grade 3/4 toxicities related to study therapy
Endpoint domain: Adverse events/effects
Primary endpoint: increased histone acetylation in surrogate tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prolonged stable disease in patients with minimal residual disease
Endpoint domain: Life impact
Primary endpoint: ACR20 response at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COG sway velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percentage seizure reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Locoregional recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: cholesterol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of FT3, FT4, TRAb, TPOAb, TGAb, and TSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Discomfort scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: expressive-grammar skills improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of transfusion of blood products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MCT time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil count on nasal cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rehospitalization within 30 days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Retention in study at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Fracture strength of instrumented femurs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mobility of the prolabium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of movement of the upper vermilion to the lower vermilion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timing of maximal speed during lip motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good and partial response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linkage to care plus 12-month retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade III or greater lung toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: HOMA-IR result of ≥75th percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of cardiac death and non-fatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: NEI‐VFQ composite scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative morphine equivalent dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported visual analog scale pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serum triglyceride level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean FA of the renal medulla
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean ADC of the renal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: eGFR correlation with medullary FA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite cognitive test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time to 1 mm ST segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: absolute weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bile viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak positive free moment amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: loading rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall HRQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Presence of TS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of TS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color of TS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure-markedly effective rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first event
Endpoint domain: Mortality/survival
Primary endpoint: hospital readmission rates
Endpoint domain: Mortality/survival
Primary endpoint: recurrence of stroke
Endpoint domain: Mortality/survival
Primary endpoint: decrease in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of cervical disease
Endpoint domain: Adverse events/effects
Primary endpoint: Development of external genital disease
Endpoint domain: Adverse events/effects
Primary endpoint: Vaccine-related adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of device insertions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean placement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence rate of postinflammatory hyperpigmentation
Endpoint domain: Adverse events/effects
Primary endpoint: Greene Climacteric Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of strokes
Endpoint domain: Mortality/survival
Primary endpoint: successful procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first recurrence of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to achieve therapeutic tacrolimus concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of out-of-range tacrolimus concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini‐Mental State Examination score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: saliva cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: nocturnal sleeping hours
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: 7-day neonatal mortality
Endpoint domain: Mortality/survival
Primary endpoint: stillbirth
Endpoint domain: Mortality/survival
Primary endpoint: McGill pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of categories selected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gray-matter density in the right pregenual ACC and left insula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Odds of developing new GA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per QALY
Endpoint domain: Resource use
Primary endpoint: Area under the plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20% response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional ability (HAQ scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global assessments (doctor and patient)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: E2, FSH, and LH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PAM score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SoC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of Type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes